Eficacia y seguridad del alprostadil intrauretral en pacientes con disfunción eréctil refractarios al tratamiento mediante inhibidores de la 5-fosfodiesterasa

Abad, Pablo Garrido; Ojas, B. Sinués; Blázquez, L.; Caturla, P. Conde; Arjona, Manuel Fernández

doi:10.1016/j.acuro.2015.04.007

Cited by 10 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The identification of more extensive small-fibre damage using CCM may allow us to identify those patients with erectile dysfunction who are less likely to respond to conventional therapies such as PDE5 inhibitors, and who should therefore be considered for daily or higher doses of PDE5 inhibitors, combination therapies or, indeed, alternative therapies such as intraurethral alprostadil or a penile prosthesis [33, 34]. …”

Section: Discussionmentioning

confidence: 99%

Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study

et al. 2017

View full text Add to dashboard Cite

Aims/hypothesisThe aim of this study was to identify the contribution of small- and large-fibre neuropathy to erectile dysfunction in men with type 1 diabetes mellitus.MethodsA total of 70 participants (29 without and 41 with erectile dysfunction) with type 1 diabetes and 34 age-matched control participants underwent a comprehensive assessment of large- and small-fibre neuropathy.ResultsThe prevalence of erectile dysfunction in participants with type 1 diabetes was 58.6%. After adjusting for age, participants with type 1 diabetes and erectile dysfunction had a significantly higher score on the Neuropathy Symptom Profile (mean ± SEM 5.3 ± 0.9 vs 1.8 ± 1.2, p = 0.03), a higher vibration perception threshold (18.3 ± 1.9 vs 10.7 ± 2.4 V, p = 0.02), and a lower sural nerve amplitude (5.0 ± 1.1 vs 11.7 ± 1.5 mV, p = 0.002), peroneal nerve amplitude (2.1 ± 0.4 vs 4.7 ± 0.5 mV, p < 0.001) and peroneal nerve conduction velocity (34.8 ± 1.5 vs 41.9 ± 2.0 m/s, p = 0.01) compared with those without erectile dysfunction. There was also evidence of a marked small-fibre neuropathy with an impaired cold threshold (19.7 ± 1.4°C vs 27.3 ± 1.8°C, p = 0.003), warm threshold (42.9 ± 0.8°C vs 39.0 ± 0.9°C, p = 0.005) and heart rate variability (21.5 ± 3.1 vs 30.0 ± 3.7 beats/min, p = 0.001) and reduced intraepidermal nerve fibre density (2.8 ± 0.7 vs 5.9 ± 0.7/mm, p = 0.008), corneal nerve fibre density (12.6 ± 1.5 vs 23.9 ± 2.0/mm2, p < 0.001), corneal nerve branch density (12.7 ± 2.5 vs 31.6 ± 3.3/mm2, p < 0.001) and corneal nerve fibre length (8.3 ± 0.7 vs 14.5 ± 1.0 mm/mm2, p < 0.001) in participants with type 1 diabetes and erectile dysfunction. Erectile dysfunction correlated significantly with measures of both large- and small-fibre neuropathy.Conclusions/interpretationSmall-fibre neuropathy is prominent in patients with type 1 diabetes, and is associated with erectile dysfunction and can be objectively quantified using corneal confocal microscopy. This may allow the identification of patients who are less likely to respond to conventional therapies such as phosphodiesterase type 5 inhibitors.

show abstract

Section: Discussionmentioning

confidence: 99%

Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study

et al. 2017

View full text Add to dashboard Cite

show abstract

Erectile dysfunction and diabetes: A melting pot of circumstances and treatments

Defeudis

Mazzilli

Tenuta

et al. 2021

Diabetes Metabolism Res

114

View full text Add to dashboard Cite

Diabetes mellitus (DM), a chronic metabolic disease characterised by elevated levels of blood glucose, is among the most common chronic diseases. The incidence and prevalence of DM have been increasing over the years. The complications of DM represent a serious health problem. The long-term complications include macroangiopathy, microangiopathy and neuropathy as well as sexual dysfunction (SD) in both men and women. Erectile dysfunction (ED) has been considered the most important SD in men with DM. The prevalence of ED is approximately 3.5-fold higher in men with DM than in those without DM. Common risk factors for the development of DM and its complications include sedentary lifestyle, overweight/ obesity and increased caloric consumption. Although lifestyle changes may help improve sexual function, specific treatments are often needed. This study aims to review the definition and prevalence of ED in DM, the impact of DM complications and DM treatment on ED and, finally, the current and emerging therapies for ED in patients with DM.

show abstract

Erectile Dysfunction: Medical Therapy and Rehabilitation

Palmieri

Capece

Giovanni

et al. 2022

Practical Clinical Andrology

View full text Add to dashboard Cite

show abstract

Eficacia y seguridad del alprostadil intrauretral en pacientes con disfunción eréctil refractarios al tratamiento mediante inhibidores de la 5-fosfodiesterasa

Cited by 10 publications

References 25 publications

Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study

Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study

Erectile dysfunction and diabetes: A melting pot of circumstances and treatments

Erectile Dysfunction: Medical Therapy and Rehabilitation

Contact Info

Product

Resources

About